ODAC Will Have Bigger Role At Avastin Hearing Than Previously Described

FDA tells the Oncologic Drugs Advisory Committee it will have a voting role at the two-day hearing, in contrast with CDER's original expectation that the panel would provide advice and recommendations but not vote.